Effect of prolactin on natural killer and MHC-restricted cytotoxic cells

NeuroImmune Biology

Volumn 2, Issue C, 2002, Pages 205-218

  Matera, Lina ^a,c   Buttiglieri, Stefano ^a,c   Moro, Francesco ^b,c   Geuna, Massimo ^b,c  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c CANDIOLO CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 29244455953     PISSN: 15677443     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1567-7443(02)80018-7     Document Type: Article

References (105)

1. Berczi I., Bertok I., and Chow D.A. Natural immunity and meuroimmune host defense. Ann NY Acad Sci 917 (2000) 248-257
2. Berczi I., Chalmers I.M., Nagy E., and Warrington R.J. The immune effects of neuropeptides. Baillière's Clinical Rheumatol 10 (1996) 227-257
3. Gala R.R. Prolactin and growth hormone in the regulation of the immune system. Proc Soc Exp Biol Med 198 (1991) 513-527
4. Kooijman R., Hooghe-Peters E.L., and Hooghe R. Prolactin, growyh hormon and insulin-like growth factor-1 in the immune system. Adv Immunol 63 (1996) 377-454
5. Matera L. Endocrine, paracrine and autocrine actions of prolactin on immune cells. Life Sci. 59 (1996) 599-614
6. Weigent D.A. Immunoregulatory properties of growth hormone and prolactin. Pharmacol Ther 69 (1996) 237-257
7. Matera L., Mori M., Geuna M., Buttiglieri S., and Palestro G. Prolactin in autoimmunity and anitumor defence. J Neuroimmunol 109 (2000) 47-55
8. Hooghe-Peters E.L., Dogusan Z., Hooghe R., and Horseman N.D. In vitro effects of prolactin on the lympho-hemopoietic system (2001), Kluwer Academic, Boston 317-339
9. Dorshkind K., and Horseman N.D. Anterior pituitary hormones, stress, and immune system homeostasis. Bioessays 23 (2001) 288-294
10. Russell D.H., Kibler R., Matrisian L., Larson D.F., Poulos B., and Magun B.E. Prolactin receptors on human T and B lymphocytes: antagonism of prolactin binding by cyclosporin. J Immunol 134 (1985) 3027-3031
11. Matera L., Muccioli G., Cesano A., Bellussi G., and Genazzani E. Prolactin receptors on large granular lymphocytes. dual regulation by cyclosporin A. Brain Behav Immun 2 (1988) 1-10
12. Pellegrini I., Lebrun J.J., Ali S., and Kelly P.A. Expression of prolactin and its receptor in human lymphoid cells. Mol Endocrinol 6 (1992) 1023-1031
13. Gagnerault M.C., Touraine P., Savino W., Kelly P.A., and Dardenne M. Expression of prolactin receptors in murine lymphoid cells in normal and autoimmune situations. J Immunol 150 (1993) 5673-5681
14. Dardenne M., Leite de Moras M.C., Kelly P.A., and Gagnerault M.-C. Prolactin receptor expression in human hematopoietic tissues analyzed by flow cytofluorimetry. Endocrinology 134 (1994) 2108-2114
15. Bresson J.L., Jeay S., Gagnerault M.C., et al. Growth hormone (GH) and prolactin receptors in human peripheral blood mononuclear cells: relation with age and GH-binding protein. Endocrinology 140 (1999) 3203-3209
16. Bellone G., Geuna M., Carbone A., et al. Regulatory action of prolactin on the in vitro growth of CD34+ve human hemopoietic progenitor cells. J Cell Physiol 163 (1995) 221-231
17. Yu-Lee L.-y. Molecular actions of prolactin in the immune system. Proc Soc Exp Biol Med 215 (1997) 35-52
18. Hooghe R, Devos S, Dogusan Z, Hooghe-Peters L. Signal transduction and modulation of gene expression by prolactin in human leukocytes. This issue.
19. Yu-Lee L. Signal transduction by prolactin receptors. This issue.
20. Clevenger C.V., Rycyzyn M.A., Syed F., and Kline J.B. Prolactin receptor signal transduction. In: Horseman N.D. (Ed). Prolactin (2001), Kluwer Academic, Boston 355-379
21. Matera L., Bellone G., Lebrun J., et al. Role of prolactin in the in vitro development of interleukin-2-driven anti-tumoral lymphokine-activated killer cells. Immunology 89 (1996) 619
22. Matera L., Galetto A., Geuna M., et al. Individual and combined effect of GM-CSF and prolactin on maturation of dendritic cells from blood monocytes under serum-free conditions. Immunology 100 (2000) 29-36
23. Bellone G., Rollino C., Borsa S., et al. Association between elevated prolactin levels and circulating erythroid precursors in dyalized patients. Proc Soc Exp Biol Med 223 (2000) 367-371
24. Bellone G., Astarita P., Artusio A., et al. Bone marrow stroma-derived prolactin is involved in basal and plateled activating factor-stimulated in vitro erythropoiesis. Blood 90 (1997) 21-27
25. Bellone G. Prolactin as a promoter of growth and differentiation of hemopoietic cells. This issue.
26. Goffin V., Binart N., Clement-Lacroix P., et al. From the molecular biology of prolactin and its receptor to the lessons learned from knockout mice models. Genet Anal 15 (1999) 189-201
27. Dorshkind K., and Horseman N.D. The roles of prolactin, growth hormone, insulin-like growth factor-I, and thyroid hormones in lymphocyte development and function: insights from genetic models of hormone and hormone receptor deficiency. Endocr Rev 21 (2000) 292-312
28. Besedovsky H.O., Sorkin E., Keller M., and Muller J. Changes in blood hormone levels during the immune response. Proc Soc Exp Biol Med 150 (1985) 466-471
29. Catthopadhyay U. Prolactin regulates macrophage and NK cell mediated inflammation and cytotoxic response against tumor. This issue.
30. Szabolcs P., Avigan D., Gezelter S., et al. Dendritic cells and macrophages can mature independently from a human bone marrow-derived post-CFU intermediate. Blood 87 (1996) 4520-4530
31. Bernton E.W., Beach J.E., Holaday J.W., Smallridge R.C., and Fein H.G. Release of multiple hormones by a direct action of interleukin-1 in pituitary cells. Science 238 (1987) 519-521
32. Banerjee R., Ginsburg E., and Vonderhaar B.K. Characterization of a monoclonal antibody against human prolactin receptors. Int J Cancer 55 (1993) 712-721
33. Whiteside T.L., and Herberman R.B. The role of natural killer cells in immune surveillance of cancer. Curr Opin Immunol 7 (1995) 704-710
34. Moretta A. Molecular mechanisms in cell-mediated cytotoxicity. Cell 90: 13-18
35. Rosemberg S.A. Immunoyherapy and gene therapy of cancer. Cancer Res. 51 (1991) 5074s
36. Vujanovic N.L., Yasumura S., Hirabayashi H., et al. Antitumor activities of subsets of human IL-2-activated Natural Killer Cells in solid tissue. J Immunol 154 (1995) 281-287
37. Vanhaesebroeck B., Grooten J., and Fiers W. An ongoing in vivo immune response affects the abundancy and differentiation of lymphokine-activated killer cell precursors, but does not influence their broad spectrum target reactivity. J Immunol 143 (1989) 1396-1407
38. Bradley M., Zeytun A., Rafi-Janajreh A., and Nagarkatti P.S. Role of spontaneous and interleukin-2-induced natural killer cell activity in the cytotoxicity and rejection of Fas+ and Fas- tumor cells. Blood 92 (1998) 4248-4255
39. Medvedev A.E., Johnsen A.C., Haux J., et al. Regulation of Fas and Fas-ligand expression in NK cells by cytokines and the involvement of Fas-ligand in NK/LAK cell-mediated cytotoxicity. Cytokine 9 (1997) 394-404
40. Frost P., Ng C.P., Belldegrun A., and Bonavida B. Immunosensitization of prostate carcinoma cell lines for lymphocytes (CTL, TIL, LAK)-mediated apoptosis via the Fas-Fas-ligand pathway of cytotoxicity. Cell Immunol 180 (1997) 70-83
41. Cooperation of Pituitary Hormone Prolactin with IL-2 and IL-12 on Production of Interferon-γ by Natural Killer and T cells. NY Acad Sci, Vol. 917.
42. Matera L., Contarini M., Bellone G., Forno B., and Biglino A. Up-modulation of interferon-gamma mediates the enhancement of spontanous cytotoxicity in prolactin-activated natural killer cells. Immunology 98 (1999) 386-392
43. Chehimi J., Valiante N.M., D'Andrea A., et al. Enhancing effect of natural killer cell stimulatory factor (NKSF/interleukin-12) on cell-mediated cytotoxicity against tumor-derived and virus infected cells. Eur J Immunol 23 8 (1993) 1826-1830
44. Matera L., and Mori M. Cooperation of pituitary hormone prolactin with interleukin-2 and interleukin 12 on production of interferon-by Natural Killer and T cells. Ann NY Acad Sci 917 (2001) 505-513
45. Oberholtzer E., Contarini M., Veglia F., et al. Prolactin increases the susceptibility of primary leukemia cells to NK and LAK effectors. Adv Neuroimmunol 6 (1996) 233-247
46. Cesano A., Oberholtzer E., Contarini M., Geuna M., Bellone G., and Matera L. Independent and synergistic effect of interleukin-2 and prolactin on development of T- and NK-derived LAK effectors. Immunopharmacol 28 (1994) 67-75
47. Gaidano G., Contarini M., Pastore C., Saglio G., and Matera L. AIDS-related Burkitt's-type lymphomas are a target for lymphokine-activated killers induced by interleukin-2 and prolactin. PSEBM 213 (1996) 196-205
48. Chakraborty A., Chakraborty N.G., and Chattopadhyay U. Prolactin response of NK cells, but not of LAK cells, is deficient in patients with carcinoma of oral cavity and during aging. Int J Cancer 66 (1996) 65-69
49. Duncan G.S., Mattrucker H.W., Kagi D., Matsuyama T., and Mak T.W. The transcription factor interferon regulatory factor-1 is essential for natural killer cell function in vivo. J Exp Med 184 (1996) 2043-2048
50. Ogasawara K., Hida S., Azimi N., Tagaya Y., Sato T., Yokochi-Fukuda T., Waldmann T.A., Taniguchi T., and Taki S. Requirement for IRF-1 in the microenvironment supporting development of natural killer cells. Nature 391 (1998) 700-703
51. Dogusan Z., Hooghe-Peters E.L., Berus D., Velkeniers B., and Hooghe R. Expression of SOCS genes in normal and leukemic human leukocytes stimulated by prolactin, growth hormone and cytokines. J Neuroimmunol 109 (2000) 34-39
52. Galon J., Sudarshan C., Ito S., Finbloom D., and O'Shea J.J. IL-12 induces IFN regulating factor-1 (IRF-1) gene expression in human NK and T cells. J Immunol 162 (1999) 7256-7262
53. Clevenger C.V., Altmann S.W., and Prystowsky M.B. Requirement of nuclear prolactin for interleukin-2-stimulated proliferation of T lymphocytes. Science 253 (1991) 77-79
54. Prystowsky M.B., and Clevenger C.V. Prolactin as a second messenger for interleukin 2. Immunomethods 5 (1994) 49-55
55. Matera L., Cesano A., Muccioli G., and Veglia F. Modulatory effect of prolactin on the DNA synthesis rate and NK activity of large granular lymphocytes. Int J Neurosci 51 (1990) 265-267
56. Triebel F., and Hercend. Subpopulations of human peripheral γδ T lymphocytes. Immunol Today 10 (1989) 186
57. Hagmann M. A trigger of natural (and other) killers. Science 285 (1999) 645-647
58. Norris S., Doherty D.G., Collins C., et al. Natural T cells in the human liver: cytotoxic lymphocytes with dual T cell and natural killer cell phenotype and function are phenotypically heterogenous and include Valpha24-JalphaQ and gammadelta T cell receptor bearing cells. Hum Immunol 60 (1999) 20-31
59. Katoh A., Ohshima K., Kanda M., et al. Gastrointestinal T cell lymphoma: predominant cytotoxic phenotypes, including alpha/beta, gamma/delta T cell and natural killer cells. Leuk Lymphoma 39 (2000) 97-111
60. Borsellino G., Poccia F., Placido R., Tramonti D., Mancino G., Luchetti S., Galgani S., Bonetti B., Bach S., Cipriani B., Brosnan C.F., and Battistini L. Phenotypic and functional properties of gamma delta T cells from patients with Guillain Barre syndrome. J Neuroimmunol 102 (2000) 199-207
61. Abs. Moro F., Geuna M., Triolo R., and Matera L. Distinct effects of Prolactin and IL-2 on proliferation and functional maturation of CD56+CD3-and CD56+CD3+NK subpopulations. Seventh Summer Symposiun in Molecular Biology. Pennstate (1998) 72
62. Taniguchi T., and Minami Y. The IL-2/IL-2 receptor system: a current overview. Cell 73 (1993) 5-8
63. Hartmann D.P., Holaday J.W., and Bernton E.W. Inhibition of lymphocyte proliferation by antibodies to prolactin. FASEB J 3 (1989) 2194-2202
64. Sabharwal P., Glaser R., Lafuse W., Varma S., Lui Q., Arkins S., Kooijman R., Kutz L., Kelly K.W., and Malakey W.B. prolactin synthesized and secreted by human peripheral blood mononuclear cell: and autocrine growth factor for lymphoproliferation. Proc Natl Acad Sci 89 (1992) 7713-7716
65. Montgomery D.W., Shen G.K., Ulrich E.D., Steiner L.L., Parrish P.R., and Zukoski C.F. Human thymocytes express a prolactin-like messenger ribonucleic acid and synthesize bioactive prolactin-like proteins. Endocrinology 131 (1992) 3019-3026
66. Kooijman R. Prolactin expression in the immune system. This issue.
67. Montgomery D.W., Krumenacker S.J., and Buckley A.R. Prolactin stimulates phosphorylation of the human T-cell antigen receptor complex and ZAP-70 tyrosine kinase: a potential mechanism for its immunomodulation. Endocrinology 139 (1998) 811-814
68. Krumenacker J.S., Montgomery D.W., Buckley D.J., Gout P.W., and Buckley A.R. Prolactin receptor signaling: shared components with the T-cell antigen receptor in Nb2 lymphoma cells. Endocrine 9 (1998) 313-320
69. Cesario T.C., Yousefi S., Carandang G., Sadati N., Le J., and Varizi N. Enhanced yields of gamma interferon in prolactin treated human peripheral blood monocytes. Proc Soc Exp Biol Med 205 (1994) 89-95
70. Viselli S.M., Stanek E.M., Mukherjee P., Hymer W.C., and Mastro A.M. Prolactin-induced mitogenesis of lymphocytes from ovariectomized rats. Endocrinology 129 (1991) 983-990
71. Matis L.A. The molecular basis of T-cell specificity. Annu Rev Immunol 8 (1990) 65-82
72. Finn O.J. Tumor-rejection antigens recognized by lymphocytes. Curr Opin Immunol 5 (1993) 701-708
73. Boon T., and Old L.J. Cancer tumor antigens. Curr Opin Immunol 9 (1997) 681-690
74. Rosemberg S.A. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 10 (1999) 281
75. Coulie P. Human tumor antigens recognized by T cells: new perspectives for anticancer vaccines. Mol Med Today 3 (1997) 261-268
76. Van den Eynde B.J., and Van der Bruggen. T cell defined tumor antigens. Curr Opin Immunol 9 (1997) 684-693
77. Germain R.N., and Margulies D.H. The biochemistry and cell biology of antigen processing and presentation. Annu Rev Immunol 11 (1993) 403-409
78. Steinman R.M. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9 (1991) 271-296
79. Banchereau J., and Steinman R. Dendritic cells and the control of immunity. Nature 392 (1998) 245
80. Galon J., Sudarshan C., Ito S., Finbloom D., O'Shea J.J., Ridge J.P., Di Rosa F., and Matzinger P.A. Conditioned dendritic cell can be a temporal bridge between a CD4+T-helper and a T-killer cell. Nature 393 (1998) 474
81. Murphy G.P., Tjoa B.A., Simmons S.J., Jarisch J., Bowes V.A., Rodge H., Rogers M., Elgamal A., Kenny G.M., Cobb O.E., Ireton R.C., Troychak M.J., Salgaller M.L., and Boynton A.L. Infusion of dendritic cells pulsed with HLA-A2 specific prostate membrane antigen peptides: a phase II prostatic cancer vaccine trial involving patients with hormone-refractory metastatic disease. The Prostate 38 (1999) 73-78
82. Bremers A.J., Andreola S., Leo E., Gallino F., et al. T cell responses in colorectal cancer patients: evidence for class II HLA-restricted recognition of shared tumor-associated antigens. Int J Cancer 88 (2000) 956-961
83. Brossart P., Wirths S., Stuhler G., Reichardt V.L., Kanz L., and Brugger W. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 96 (2000) 3102-3108
84. Alters S.E., Gadea J.R., Sorich M., et al. Dendritic cells pulsed with CEA peptide induced CEA specific CTL with restricted TCR repertoire. J Immunother 21 (1998) 17-26
85. Tsang K.Y., Zaremba S., Nieroda C.A., Zhu M.Z., Hamilton J.M., and Schlom J. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst 87 (1995) 982
86. Morse M.A., Deng Y., Coleman D., Hull S., Kitrell-Fisher E., Nair S., Schlom J., Ryback M.E., and Lyerly H.K. A phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin Cancer Res 5 (1999) 1331-1338
87. Chouaib S., Asselin-Paturel, Mami-Chouab F., Caignar A., and Blay J.Y. The host-tumor immune conflict: from immunosuppression to resistance and desctruction. Immunol Today 18 (1997) 493-497
88. Besedovsky H.O., Sorkin E., Keller M., and Muller J. Changes in blood hormone levels during the immune response. Proc Soc Exp Biol Med 150 (1985) 466-471
89. Sallusto F., and Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocute-macrophage colony stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 179 (1994) 1109-1994
90. Zhou L.J., and Tedder T.F. CD14+blood monocytes can differentiate into functionally mature CD83+dendritic cells. Proc Natl Acad Sci 93 (1996) 2588
91. Romani N., Reider D., Heuer M., Ener S., Eibl B., and Schuler G. Generation of mature dendritic cells from human blood: an improved method with special regard to clinical applicability. J Immunol Methods 196 (1996) 137
92. Romero P., Cerottini J.C., and Waanders G.A. Novel methods to monitor antigen-specific cytotoxic T-cell responses in cancer immunotherapy. Mol Med Today 4 (1998) 305
93. Herr W., Linn B., Leister N., Wandel E., Meyer Zum Buschenfelde K.H., and Wolfel T. The use of computer-assisted video image analysis for the quantification of CD8+T lymphocytes producing tumor necrosis factor alpha spots in response to peptide antigens. J Immunol Methods 203 (1997) 141
94. Matera L., Ciccarelli E., Muccioli G., Cesano A., Grottoli S., Oberholtzer E., and Camanni F. Normal development of lymphokine activated killing (LAK) in peripheral blood lymphocytes from hyperprolactinemic patients. Int J Immunopharmacol 14 7 (1992) 1235-1240
95. Wells J.A., and de Vos A.M. Structure and function of human growth hormone: implication for the hematopoietin. Ann Rev Biophys Miomol Structures 22 (1993) 329-351
96. Matera L., Cutufia M., Geuna M., Contarini M., Buttiglieri S., Galin S., et al. Prolactin is an autocrine growth factor for the Jurkat human T-leukemic cell line. J Neuroimmunol 79 (1997) 12-21
97. Di Mattia G.E., Gellersen B., Bohnet H.G., and Friesen H.G. A human B-lymphoblastoid cell line produces prolactin. Endocrinology 122 (1988) 2508-2518
98. Hooghe R., Merchav S., Gaidano G., Naessens F., and Matera L. A role for growth hormone and prolactin in leukaemia and lymphoma?. Cell Mol Life Sci 54 (1998) 1095-1101
99. Matera L., Geuna M., Pastore C., Buttiglieri S., et al. Expression of prolactin and prolactin receptors by non-hodgkin's lymphoma cells. Int J Cancer 85 (2000) 124-130
100. Hatfill S.J., Kirby R., Hanley M., Rybicki E., and Bohm L. Hyperprolactinemia in acute myeloid leukemia and indication of ectopic expression of human prolactin in blast cells of a patient of subtype M4. Leuk Res 14 (1990) 57-62
101. Kooijman R., Gerlo S., and Coppens A. Myeloid leukemic cells express and secrete bioactive pituitary-sized 23 kDa prolactin. J Neuroimmunol 110 (2000) 252-258
102. Bhatavdekar J., Vora H., Balar D., Patel D., et al. Interrelationship of prolactin and its receptor in carcinoma of colon and rectum: a preliminary report. J Surg Oncol 55 (1994) 246-249
103. Ilan Y., Sibersky O., Livni N., Gofrit O., Barack V., and Goldin E. Plasma and tumor prolactin in colorectal cancer patients. Dig Dis Sci 40 (1995) 2010-2015
104. Richards SM. Human prolactin as an immunohematopoietic factor: implications for the clinic. This issue.
105. Woody M.A., Welniak L.A., Sun R., Tian Z.G., Henry M., Richards S., et al. Prolactin exerts hematopoietic growth-promoting effects in vivo and partially counteracts myelosuppression by azidothymidine. Exp Hematol 27 (1999) 811-816